As a proof of concept for the dual in vitro and in vivo use of Py2T cells as models of murine breast cancer cells undergoing EMT, we blocked TGFβ responsiveness of Py2T cells by stable expression of a dominant-negative version of TGFβRII. This evidence concerns the gene TGFB1 and breast carcinoma.